Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693323 · ClinicalTrials.gov registry record · Phase 2
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
A Phase 2 study of Head and Neck Squamous Cell Carcinoma and HNSCC, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06693323 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma and HNSCC that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 34 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06693323, a Phase 2 study of Head and Neck Squamous Cell Carcinoma and HNSCC, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.
Conditions Studied
Interventions
- DRUG AHCC®capsules
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693323
The ClinicalTrials.gov registry entry for NCT06693323 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AHCC®capsules is the first listed.
NCT06693323 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06693323 about?
NCT06693323 is a clinical study titled "Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC". This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.
What is the current status of trial NCT06693323?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2024-12-04. Estimated completion is 2027-12.
What conditions does trial NCT06693323 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, HNSCC.
What interventions are being tested in trial NCT06693323?
The interventions under investigation include: AHCC®capsules (DRUG).
Who is sponsoring clinical trial NCT06693323?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693323 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.